Deepak Bhatt

Director of Mount Sinai Heart and Dr. Valentin Fuster Professor of Cardiovascular Medicine

Icahn School of Medicine at Mount Sinai

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Deepak Bhatt is the Director of Mount Sinai Heart and serves as the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai, USA. His research focuses on cardiovascular health, with recent articles exploring topics such as aortic stenosis management, the impact of omega-3 fatty acids on cardiovascular mortality, and the use of polygenic risk scores for predicting heart failure. He aims to improve patient outcomes through advanced therapeutic strategies and innovation in diagnostic techniques.

Articles (30)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (18)

Brian Mac Grory

Assistant Professor

Duke University School of Medicine

UNITED STATES

Deepak Bhatt

Research Interests

Explore related searches

Contact this professor

About

Articles (30)

Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy

Eicosapentaenoic acid (EPA) limits the more rapid oxidation of lipoprotein(a) [Lp(a)] compared with other ApoB particles

Acute coronary syndromes: mechanisms, challenges, and new opportunities

Early Intervention vs Conservative Management in Severe Asymptomatic Aortic Stenosis

Effects of Eicosapentaenoic Acid vs Eicosapentaenoic/Docosahexaenoic Acids on Cardiovascular Mortality

Benefit of Icosapent Ethyl Across Types and Sizes of Myocardial Infarction in REDUCE-IT

Representation of Older Adults and Women in Randomized Trials of Noninvasive Imaging for Chest Pain

A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of Cardiovascular Risk

Optimal medical therapy for initial management of stable angina: a call to action

Fully Automated Diagnosis of Acute Myocardial Infarction Using Electrocardiograms and Multimodal Deep Learning

Interdisciplinary Engagement In Neurocardiology: A Key Opportunity

Bleeding and Thrombosis in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention

Clonal hematopoiesis, cardiovascular events and treatment benefit in 63,700 individuals from five TIMI randomized trials

Competing Risks in Clinical Trials

Cost-Effectiveness of Sotagliflozin in SOLOIST-WHF

Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure

Origins and Previous Applications of Causal-Benefit Models

Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome

Multimodal fusion learning for long QT syndrome pathogenic genotypes in a racially diverse population

Valvular Heart Disease-Related Mortality Between Middle- and High-Income Countries During 2000 to 2019

Mortality in Patients Hospitalized With Acute Myocardial Infarction Without Standard Modifiable Risk Factors: The ARIC Study Community Surveillance

Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial

Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction

Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of Three Tests

Pleiotropic Effects of Influenza Vaccination

Cardiovascular Effects of GnRH Antagonists Compared With Agonists in Prostate Cancer

Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events

Role of Cardiovascular Imaging in Risk Assessment: Recent Advances, Gaps in Evidence, and Future Directions

Semaglutide reduces the risk of major adverse cardiovascular events consistently across baseline triglyceride levels in patients with type 2 diabetes: Post hoc analyses of the SUSTAIN 6 and PIONEER 6 trials

Effect of sotagliflozin on albuminuria in patients with type 2 diabetes and chronic kidney disease

Collaborators (18)

Brian Mac Grory

Mads Kjolby

Nicholas Marston

Carlos Garcia Santos-Gallego

Pierre Sabouret

Vera Bittner

J. Wouter Jukema

Philippe Gabriel Steg

James Pirruccello

Giuseppe Biondi-Zoccai

Luigi Spadafora

Sripal Bangalore

Subodh Verma

Peter Libby

Astrid Johannesson Hjelholt

Marco Metra

Francesco Cosentino

Marco Bernardi

Make your next move.